FOR AUTHORS
Search
Search Results
##search.searchResults.foundPlural##
-
-
11 | EFFICACY AND SAFETY OF LEBRIKIZUMAB IS MAINTAINED UP TO 4 YEARS IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS: FIRST YEAR OF ADLONG LONG-TERM EXTENSION TRIAL L. Stingeni1, S. Weidinger2, A. Irvine3, D. Thaçi4, J. Szepietowski5, T. Biedermann6, H. Agell7, Y. Mihaylov7, B. Kostov7, R. Coll7, W. Romero8, K. Reich9 | 1Dermatology Section, Department of Medicine and Surgery, University of Perugia, Italy; 2Department of Dermatology and Allergy, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany; 3Department of Clinical Medicine, Trinity College Dublin, Dublin, Ireland; 4Institute and Comprehensive Center for Inflammatory Medicine at the University of Lübeck, Lübeck, Germany; 5Division of Dermatology, Venereology and Clinical Immunology, Faculty of Medicine, Wrocław University of Science and Technology, Wrocław, Poland; 6Department of Dermatology and Allergy, Technical University of Munich, School of Medicine and Health, Munich, Germany; 7Almirall S.A., Barcelona, Spain; 8Eli Lilly and Company, Indianapolis, IN, USA; 9Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
141PDF: 85 -
Metastatic basal cell carcinoma to the bone: a case of bone metastasis in uncommon sites
1143PDF: 540Supplementary Table: 256HTML: 26 -
10 | LEBRIKIZUMAB PROVIDES CLINICALLY MEANINGFUL RESPONSE IN FACE AND HANDS IN ADULTS AND ADOLESCENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS: ADHOPE 1 STUDY L. Stingeni1, C. Vestergaard2, J. Seneschal3|4, S. Weidinger5, A. Wollenberg6|7|8, A. Irvine9, H. Agell10, J. Valls Bancells10, V. Sapena10, D. Thaçi7 | 1Dermatology Section, Department of Medicine and Surgery, University of Perugia, Italy; 2Department of Dermatology and Venerology, Aarhus University Hospital, Aarhus, Denmark; 3Department of Dermatology, University of Bordeaux, Bordeaux, France; 4Department of Dermatology and Pediatric Dermatology, National Reference Center for Rare Skin Disorders, Hospital Saint-André, Bordeaux, France; 5Department of Dermatology and Allergy, University Hospital Schleswig-Holstein, Kiel, Germany; 6University Medical Center of Augsburg, Augsburg, Germany; 7Institute and Comprehensive Center for Inflammatory Medicine at the University of Lübeck, Lübeck, Germany; 8Department of Dermatology and Allergology, LMU Hospital, Munich, Germany; 9Department of Clinical Medicine, Trinity College Dublin, Dublin, Ireland; 10Almirall S.A., Barcelona, Spain
231PDF: 161

